Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Short-chain three-finger alpha-neurotoxins (Sc3FTxs) are a major class of toxic polypeptides found in the venom of elapid snakes, such as cobras, kraits, and sea snakes. These toxins are characterized by a conserved structural motif consisting of three beta-stranded loops extending from a central hydrophobic core, stabilized by four conserved disulfide bonds. Their primary biological function is the high-affinity, competitive antagonism of muscle-type nicotinic acetylcholine receptors (nAChR) at the postsynaptic membrane of the neuromuscular junction. By binding to the orthosteric site of the receptor, Sc3FTxs block the action of the neurotransmitter acetylcholine, leading to a failure of neuromuscular transmission. This results in rapid flaccid paralysis of skeletal muscles, which can progress to fatal respiratory failure if not treated promptly. In clinical practice, these toxins are the primary targets for neutralization by polyclonal antivenoms, although their small molecular size and low immunogenicity present significant therapeutic challenges. Ongoing research aims to develop more effective treatments, including broadly neutralizing monoclonal antibodies and synthetic inhibitors, to improve outcomes for snakebite victims.
Neutralization of the toxin through steric hindrance or competitive binding, preventing the toxin from interacting with its physiological target (nAChR).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Short-chain three-finger alpha-neurotoxin (Sc3FTx).